Our website uses cookies to improve your on-site experience. By using the website, cookies are being used as described in our Policy Document
Warning: To log in you will need to enable cookies and reload the page (Policy Document)
My ePortfolio Register   

TATTON: Osimertinib plus savolitinib for patients with EGFR-mutant, MET-amplified NSCLC after progression on EGFR-TKI

Please rate this video

Please complete at least one question.

  1. The information in this video was of interest to me Disagree Agree
  2. The information in this video is likely to improve my clinical practice or research Disagree Agree
  3. I would recommend this video to my colleagues Disagree Agree
Submit
Thanks for rating
There has been a problem, please refresh and try again.
Published: 15.04.19
Views: 666

Prof Lecia Sequist - Massachusetts General Hospital, Boston, USA

Prof Lecia Sequist speaks to ecancer at the 2019 American Association for Cancer Research (AACR) meeting about the TATTON study looking at osimertinib plus savolitinib for patients with EGFR-mutant, MET-amplified NSCLC after progression on fist/second generation EGFR-TKI or third generation EGFR-TKI.

She reports that patients that were biomarker selected due to their MET driven resistance are responding well to the EGFR plus MET combination.

Prof Sequist informs that patients who previously received a first/second generation EGFR inhibitor (and are T790-negative and MET-positive) had a response rate of 52% compared with 25% for patients who received a third generation drug.

Read more about this research here.

Related videos

18.06.19

no rating
Cancer care in Latin America

follow us

Core Surgical Training


Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

ecancer Global Foundation